ROME (ITALPRESS) – “There are tests that waste your time. Others, on the other hand, make you gain it.” This is the key message that EuropaColon Italia APS, with the unconditional support of Pierre Fabre Pharma, will spread on its official social channels (primarily Facebook and YouTube, as well as X) during the awareness campaign called “The Infinite Test.” A campaign to raise awareness of testing for genetic mutations in metastatic colorectal cancer to the broader population, and which will run throughout the month of December through the main social media.A diagnosis of metastatic colorectal cancer is very painful news for both patients and their families, but today, thanks to advances in medical research, it is possible to approach a course of treatment with personalized therapeutic schemes based precisely on the identification of molecular “target” mutations against which to direct targeted drugs, in full compliance with personalized medicine.In Italy in 2023 there were about 50,500 new diagnoses of colorectal cancer and in about 30 percent of cases the disease manifested itself in the presence of distant metastases to the liver and/or lungs; and it is precisely in these cases that molecular tests are indispensable, because they allow to analyze the genetic characteristics of the tumor and plan, therefore, a personalized treatment. The Campaign, through classic pastime games circulating in social media, aims to attract users’ attention by testing them with fun quizzes designed especially for the Campaign. The game will be the vehicle to reveal the key message: the importance of molecular testing for detecting genetic mutations in metastatic colorectal cancer. The goal is to reach as many people as possible through the simple but engaging mechanism called “endless testing,” turning each of us into a Campaign ambassador by sharing the initiative with family and friends.”The long-term prognosis and prospects of cure even in cases of stage IV colorectal cancer have significantly improved over the past few years thanks to the availability of cutting-edge treatments such as immunotherapy and target therapy, which in turn are based on tests that allow tumors to be defined through their genetic and molecular profile,” emphasizes EuropaColon Italia APS President Roberto Persiani, Associate Professor of General Surgery at the Università Cattolica del Sacro Cuore, Rome campus and Head of the UOS of Minimally Invasive Surgery at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS, along with Laura Lorenzon, member of the Board of Directors of EuropaColon Italia APS and Medical Director of the UOC of General Surgery at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS.”Metastatic disease represents one of the most complex challenges for physicians, who are faced not with a single colorectal cancer, but with a variety of tumors with different characteristics and therapeutic responses,” comments Charles Henri Bodin, CEO Pierre Fabre Pharma in Italy. “It is essential that pharmaceutical companies continue to invest in the search for innovative therapies capable of hitting specific targets. These targets must be identified through molecular tests, but the results of these tests must arrive in a timely manner, especially in cases of advanced disease. “The “infinite tests” will be available at www.infinitetest.it for the duration of the campaign, while at www.europacolon.it the in-depth page on molecular tests for the detection of genetic mutations in colorectal cancers will remain active at all times, with all the useful information for patients, caregivers and all those who want in-depth information.In addition, the new Campaign also offers a video contribution from 3 medical specialists: Elisabetta Fenocchio, Oncologist at the Candiolo Cancer Institute in Turin, Matteo Fassan, Director of the Department of Pathology at Cà Foncello Hospital in Treviso, and Anna Costantini, Psycho-Oncologist and Vice President of the Italian Federation of Psychology Societies. Through the interviews on the website and conducted exclusively, people with this cancer and their family members will be able to get valuable information about molecular testing and the disease, as well as simple and clear advice on how to cope with it.
– Photo EuropaColon Italia APS press office –
(ITALPRESS).
